secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2023-08-16T23:59:59+00:00
Accession:  0001193125-23-214303
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic and Roche amend collaboration; IBD option deadline extended to Jan 15, 2024 or later
--------------------------------------------------------------------------------

- Roche holds exclusive option to negotiate a license for Synlogic's IBD Synthetic Biotic medicine.
- Amendment extends option deadline to later of Jan 15, 2024 or 90 days after data delivery.
- Original collaboration agreement effective June 16, 2021; amendment executed August 16, 2023.
- Synlogic to deliver certain research data before the 90-day extension trigger.
- No other changes to collaboration terms were disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000119312523214303/0001193125-23-214303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000119312523214303/d539351d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-214303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer